Membrane-associated lipophilic structures in neovascular endothelium

Membrane-associated lipophilic structures in neovascular endothelium refer to the lipid-rich cellular components, specifically the mitochondrial and endoplasmic reticulum membranes, within the endothelial cells of pathological new blood vessels (FDA Visudyne Label, 2013). These structures are the primary site of action for the photodynamic therapy (PDT) agent verteporfin, also known as Visudyne (DrugBank, DB00460). Verteporfin is a lipophilic drug that is transported in the blood by low-density lipoproteins (LDL) and is selectively taken up by neovascular endothelial cells due to their high expression of LDL receptors (Schmidt-Erfurth et al., 2000). Once localized within these membrane structures, the drug is activated by a non-thermal laser of a specific wavelength, leading to the production of reactive oxygen species (ROS) such as singlet oxygen (NIH, PubChem CID 5362420). This localized oxidative stress causes immediate damage to the endothelial cell membranes, triggering a cascade of events including platelet aggregation, fibrin clot formation, and ultimately the occlusion of the abnormal vessels (Michels & Schmidt-Erfurth, 2001). This targeted approach is used to treat conditions like wet age-related macular degeneration (AMD), where it helps to close leaky vessels and prevent further vision loss while sparing the surrounding healthy retinal tissue (StatPearls, 2023). A significant therapeutic challenge is the resulting systemic photosensitivity, requiring patients to avoid direct sunlight for several days following treatment (StatPearls, 2023).

Other names

Neovascular endothelial membranesMitochondrial and endoplasmic reticulum membranes of neovascular cellsLipophilic structures of neovascular endothelium

Photodynamic therapy (PDT) involving the generation of reactive oxygen species (ROS) upon light activation, leading to membrane damage and vascular occlusion (FDA Visudyne Label, 2013).